Mostrar el registro sencillo del ítem
| dc.contributor.author | Carmona-Bayonas, Alberto | |
| dc.contributor.author | Jiménez-Fonseca, Paula | |
| dc.contributor.author | Capdevila, Jaume | |
| dc.contributor.author | Alonso, Vicente | |
| dc.contributor.author | Benavent, Marta | |
| dc.contributor.author | López-López, Carlos | |
| dc.contributor.author | Ruffinelli, José-Carlos | |
| dc.contributor.author | Crespo, Guillermo | |
| dc.contributor.author | Nosti, Laura | |
| dc.contributor.author | San-Roman-Gil, María | |
| dc.contributor.author | Marín-Zafra, Gema-Rocío | |
| dc.contributor.author | Hernando, Jorge | |
| dc.contributor.author | Azpiroz, Mónica-Marazuela | |
| dc.contributor.author | Castano, Angel | |
| dc.contributor.author | García-Carbonero, Rocio | |
| dc.date.accessioned | 2026-11-11T09:07:22Z | |
| dc.date.available | 2026-11-11T09:07:22Z | |
| dc.date.issued | 2026-11 | |
| dc.identifier.citation | Carmona-Bayonas A, Jimenez-Fonseca P, Capdevila J, Alonso V, Benavent M, Lopez-Lopez C, et al. Perioperative chemotherapy and long-term cure in resected grade 3 gastroenteropancreatic neuroendocrine carcinomas: The GETNE SOUTH-NEC Study. European Journal of Cancer. noviembre de 2026;248:117773. doi:10.1016/j.ejca.2026.117773 | |
| dc.identifier.issn | 0959-8049 | |
| dc.identifier.uri | https://sms.carm.es/ricsmur/handle/123456789/29208 | |
| dc.description.abstract | BACKGROUND: In resected stage I-III gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC), whether perioperative chemotherapy eradicates residual disease or merely delays relapse is unknown, since Cox models cannot distinguish these effects. METHODS: We analysed 162 patients with resected stage I-III GEP-NEC from the GETNE registry. Event-free (EFS), recurrence-free (RFS) and overall survival (OS) were modeled by Cox regression with chemotherapy as a time-dependent exposure, adjusted for age, sex, performance status, stage, Ki-67 and site, and by a Bayesian promotion-time cure model that separates a clonogenic (cure) component from a kinetic (relapse timing) component. RESULTS: Seventy-four patients (46%) received chemotherapy; median follow-up was 93 months. Chemotherapy was associated with longer EFS (hazard ratio [HR], 0.61; 95% confidence interval [CI], 0.40-0.96) and RFS (HR, 0.59; 95% CI, 0.37-0.93), but not clearly with OS (HR, 0.73; 95% CI, 0.46-1.15). On EFS, the cure model attributed the association to a lower clonogenic burden (ratio, 0.67; 95% credible interval [CrI], 0.40-1.11; posterior probability, 94%) rather than to slower kinetics (ratio, 0.93); on RFS both components contributed. The population cure fraction was 22.7% (95% CrI, 15.9-29.6) for EFS and 28.6% (21.9-35.7) for RFS, matching the Kaplan-Meier plateaus. No Ki-67 by chemotherapy interaction was detected. CONCLUSION: In resected grade 3 GEP-NEC, perioperative chemotherapy is associated with longer EFS and RFS and, on the composite endpoint, with a higher probability of long-term cure rather than delayed recurrence. These associations are observational and the cure-versus-delay decomposition is descriptive. Cure models add information beyond conventional survival metrics. | |
| dc.language.iso | eng | |
| dc.publisher | ELSEVIER SCI LTD | |
| dc.rights | Atribución/Reconocimiento-NoComercial-SinDerivados 4.0 Internaciona | |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | * |
| dc.subject.mesh | Humans | |
| dc.subject.mesh | Female | |
| dc.subject.mesh | Male | |
| dc.subject.mesh | Pancreatic Neoplasms/pathology/drug therapy/mortality/surgery | |
| dc.subject.mesh | Middle Aged | |
| dc.subject.mesh | Aged | |
| dc.subject.mesh | Carcinoma, Neuroendocrine/pathology/drug therapy/mortality/surgery | |
| dc.subject.mesh | Intestinal Neoplasms/pathology/drug therapy/mortality/surgery | |
| dc.subject.mesh | Stomach Neoplasms/pathology/drug therapy/mortality/surgery | |
| dc.subject.mesh | Chemotherapy, Adjuvant | |
| dc.subject.mesh | Neoplasm Grading | |
| dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols/therapeutic use | |
| dc.subject.mesh | Adult | |
| dc.subject.mesh | Time Factors | |
| dc.subject.mesh | Registries | |
| dc.subject.mesh | Neoplasm Recurrence, Local | |
| dc.subject.mesh | Neuroendocrine Tumors | |
| dc.title | Perioperative chemotherapy and long-term cure in resected grade 3 gastroenteropancreatic neuroendocrine carcinomas: The GETNE SOUTH-NEC Study | |
| dc.type | info:eu-repo/semantics/article | |
| dc.identifier.pmid | 42869860 | |
| dc.relation.publisherversion | https://linkinghub.elsevier.com/retrieve/pii/S0959804926015558 | |
| dc.type.version | info:eu-repo/semantics/publishedVersion | |
| dc.identifier.doi | 10.1016/j.ejca.2026.117773 | |
| dc.journal.title | European Journal of Cancer | |
| dc.identifier.essn | 1879-0852 |